Wall Street Zen Downgrades INmune Bio (NASDAQ:INMB) to Sell

INmune Bio (NASDAQ:INMB) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

INmune Bio Stock Performance

Shares of NASDAQ:INMB opened at $1.62 on Friday. The firm has a market cap of $43.06 million, a price-to-earnings ratio of -0.97 and a beta of 0.97. The firm has a fifty day moving average price of $1.55 and a 200 day moving average price of $1.46. INmune Bio has a fifty-two week low of $1.09 and a fifty-two week high of $3.24.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its stake in INmune Bio by 44.8% during the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after acquiring an additional 9,236 shares during the last quarter. Jane Street Group LLC bought a new position in shares of INmune Bio during the 1st quarter valued at approximately $142,000. Rhumbline Advisers increased its position in shares of INmune Bio by 14.4% during the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after purchasing an additional 2,409 shares during the last quarter. Geode Capital Management LLC raised its holdings in INmune Bio by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock valued at $901,000 after buying an additional 25,069 shares during the period. Finally, Intech Investment Management LLC bought a new stake in INmune Bio in the second quarter worth $26,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.